Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Colon cancer is a common malignant tumor of the gastrointestinal system, which is characterized by high morbidity and mortality. The purpose of this study was to analyze the expression and biological role of miR-181a-2-3p in colon cancer and to investigate the molecular mechanism of its regulatory effect on colon cancer through stimulator of interferon genes (STING).
Methods: Real-time reverse transcription polymerase chain reaction (qRT-PCR) assay was used to detect the expression of miR-181a-2-3p in colon cancer cell lines and normal intestinal epithelial cells. After overexpression of miR-181a-2-3p in colon cancer cell lines SW480 and HT29, cells were examined by CCK8, Transwell, and flow cytometry assays for alterations in proliferation, migration, apoptosis, and cell cycle. Target genes of miR-181a-2-3p were predicted by bioinformatics and validated by dual luciferase assays. Rescue experiments were performed to explore the role of STING in the effect of miR-181a-2-3p. The effect of miR-181a-2-3p on colon cancer proliferation was validated by nude mouse tumorigenicity assay.
Results: miR-181a-2-3p was lowly expressed in both colon cancer tissues and cell lines. Overexpression of miR-181a-2-3p led to reduced proliferation and migration, increased apoptosis, and altered cell cycle in colon cancer cell lines SW480 and HT29. STING was a target gene of miR-181a-2-3p. Increased STING expression partially counteracted the effect of overexpression of miR-181a-2-3p on colon cancer cell lines. miR-181a-2-3p also suppressed colon cancer proliferation .
Conclusion: miR-181a-2-3p inhibits the proliferation and oncogenicity of colon cancer, and its molecular mechanism could be inhibited by STING.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346793 | PMC |
| http://dx.doi.org/10.18632/aging.206059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, treatment, and survival of patients with appendiceal adenocarcinomas and low-grade appendiceal mucinous neoplasms: linked Swedish national registry study.
BJS Open
September 2025
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Background: Appendiceal adenocarcinomas and low-grade appendiceal mucinous neoplasms (LAMNs) are rare tumours. Much of the existing knowledge is derived from registry-based studies, particularly the Surveillance, Epidemiology, and End Results database in the USA.
Methods: This retrospective cohort study used data from the Swedish Cancer Registry, Swedish Cause of Death Registry, and the National Patient Registry to analyse demographic characteristics and outcomes of patients diagnosed with appendiceal adenocarcinoma or LAMN between 2005 and 2019.
[Interleukin-6 as a biochemical marker of intestinal anastomotic leakage].
Khirurgiia (Mosk)
September 2025
Saint Petersburg State University, Saint Petersburg, Russia.
Objective: To evaluate diagnostic significance of IL-6 compared to CRP for early detection of anastomotic leakage after colon resection for colorectal cancer.
Material And Methods: The study included 277 patients who underwent total resection for colorectal cancer. Patients were retrospectively divided into three groups: without complications (=227), with anastomotic leakage (=30), and other postoperative complications (=20).
Pilot Study: Identification of the T Cell Tumor Microenvironment of Premalignant and Malignant Anal Lesions.
Dis Colon Rectum
September 2025
Department of Surgery, Oregon Health & Science University, Portland, Oregon.
Background: Anal squamous cell cancer incidence has risen 2.2% each year over the past decade. Current screening includes anal cytology and high-resolution anoscopy but is burdened with sampling error and patient discomfort.
View Article and Find Full Text PDFAdjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.
Cancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFOptimal Extent of Lymph Node Dissection for Non-Metastatic Colon Cancer by Tumor Location: Evaluation of the Therapeutic Value Index for Each Lymph Node Station.
Ann Gastroenterol Surg
September 2025
Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Aims: To determine the optimal extent of lymph node dissection for non-metastatic colon cancer by tumor location based on the therapeutic value index (TVI) for each lymph node station.
Methods: Consecutive patients with surgical stage I-III colon or rectosigmoid cancer in the Japanese Society for Cancer of the Colon and Rectum database who underwent curative resection between January 2003 and December 2014 were analyzed. The TVI was defined as the incidence of lymph node metastasis multiplied by 5-year overall survival and calculated for each nodal station stratified by tumor location.